Figure 2From: Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study Proportion of patients who maintained remission (relapse-free) at Week 26 or Week 52 and did not receive additional treatment for Crohn's disease. biw: twice weekly; IFN: interferon; tiw: three times weekly. *p < 0.05 in favour of placebo over IFN beta-1a 66 mcg tiw at Week 52.Back to article page